Literature DB >> 14737060

Measles mortality reduction--West Africa, 1996-2002.

.   

Abstract

The World Health Organization (WHO) estimates that, during 2000, measles accounted for approximately 777,000 deaths worldwide, of which 452,000 (58%) occurred in Africa. In response, in 2000, WHO's African Regional Office (AFRO) adopted a plan to reduce measles mortality >50% by 2005. The plan recommended 1) increasing measles vaccination by strengthening routine health services; 2) providing a second opportunity for measles vaccination for all children, primarily through wide--age-range supplemental immunization activities (SIAs); 3) enhancing measles surveillance; and 4) improving management of measles cases. The initial wide--age-range SIA targets all children aged 9 months-14 years, regardless of history of measles disease or vaccination. Follow-up SIAs are needed 3-5 years after the initial SIA to provide a second opportunity for vaccination to children born since the previous SIA (i.e., those aged 9 months-4 years). During the 1990s, the countries of the Americas and seven countries in southern Africa used this strategy to reduce the number of measles deaths to near zero. This report describes the recent implementation of this strategy in three West African countries, where reported measles cases declined 83%-97% during the first year after SIAs. Successful implementation of this strategy by other African countries should result in achieving the goal of >50% reduction in measles mortality by 2005.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14737060

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  4 in total

1.  Epidemiological impact of a nationwide measles immunization campaign in Viet Nam: a critical review.

Authors:  Hitoshi Murakami; Nguyen Van Cuong; Hong Van Tuan; Katsuyuki Tsukamoto; Do Si Hien
Journal:  Bull World Health Organ       Date:  2008-12       Impact factor: 9.408

2.  Characterization of immune responses induced by intramuscular vaccination with DNA vaccines encoding measles virus hemagglutinin and/or fusion proteins.

Authors:  Man Ki Song; Christofer J Vindurampulle; Alejandra V E Capozzo; Jeffrey Ulmer; John M Polo; Marcela F Pasetti; Eileen M Barry; Myron M Levine
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

Review 3.  Emerging diseases: measles.

Authors:  Martin O Ota; William J Moss; Diane E Griffin
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

4.  Unacceptably high mortality related to measles epidemics in Niger, Nigeria, and Chad.

Authors:  R F Grais; C Dubray; S Gerstl; J P Guthmann; A Djibo; K D Nargaye; J Coker; K P Alberti; A Cochet; C Ihekweazu; N Nathan; L Payne; K Porten; D Sauvageot; B Schimmer; F Fermon; M E Burny; B S Hersh; P J Guerin
Journal:  PLoS Med       Date:  2007-01       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.